Wincap Financial LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Wincap Financial LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 11.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,382 shares of the biopharmaceutical company’s stock after purchasing an additional 2,026 shares during the quarter. Wincap Financial LLC’s holdings in Bristol Myers Squibb were worth $897,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Motley Fool Asset Management LLC lifted its holdings in shares of Bristol Myers Squibb by 5.5% during the 2nd quarter. Motley Fool Asset Management LLC now owns 99,576 shares of the biopharmaceutical company’s stock worth $4,609,000 after acquiring an additional 5,179 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in Bristol Myers Squibb by 20.8% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 473,506 shares of the biopharmaceutical company’s stock worth $21,919,000 after purchasing an additional 81,600 shares during the period. Rossby Financial LCC boosted its holdings in shares of Bristol Myers Squibb by 25.6% in the 2nd quarter. Rossby Financial LCC now owns 2,560 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 521 shares during the last quarter. AustralianSuper Pty Ltd grew its stake in shares of Bristol Myers Squibb by 18.5% during the 2nd quarter. AustralianSuper Pty Ltd now owns 3,232,919 shares of the biopharmaceutical company’s stock valued at $149,652,000 after buying an additional 503,930 shares during the period. Finally, Teacher Retirement System of Texas increased its holdings in shares of Bristol Myers Squibb by 6.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 1,039,588 shares of the biopharmaceutical company’s stock worth $48,123,000 after buying an additional 64,440 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the subject of a number of research reports. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have given a Hold rating to the company. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $57.23.

Bristol Myers Squibb Stock Down 1.0%

Shares of NYSE:BMY opened at $43.39 on Tuesday. The company has a market capitalization of $88.31 billion, a price-to-earnings ratio of 17.49, a price-to-earnings-growth ratio of 2.29 and a beta of 0.33. The company has a 50 day moving average of $45.65 and a two-hundred day moving average of $46.98. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the prior year, the firm earned $2.07 earnings per share. The business’s quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.7%. Bristol Myers Squibb’s payout ratio is 100.00%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.07% of the company’s stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.